{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T19:13:09Z","timestamp":1781118789993,"version":"3.54.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82001758"],"award-info":[{"award-number":["82001758"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32270969"],"award-info":[{"award-number":["32270969"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-025-08520-y","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T15:28:35Z","timestamp":1753716515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["OH2 oncolytic virus inhibits non-small-cell lung cancer metastasis via \u03b2-catenin pathway suppression"],"prefix":"10.1038","volume":"8","author":[{"given":"Han","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaiqi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixiao","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2852-600X","authenticated-orcid":false,"given":"Binlei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"8520_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics. 2023. Ca. Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"Ca. Cancer J. Clin."},{"key":"8520_CR2","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jama.2019.11058","volume":"322","author":"KC Arbour","year":"2019","unstructured":"Arbour, K. C. & Riely, G. J. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA 322, 764\u2013774 (2019).","journal-title":"JAMA"},{"key":"8520_CR3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2217\/fon-2019-0348","volume":"15","author":"JC Simeone","year":"2019","unstructured":"Simeone, J. C., Nordstrom, B. L., Patel, K. & Klein, A. B. Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting. Future Oncol. 15, 491\u2013502 (2019).","journal-title":"Future Oncol."},{"key":"8520_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","volume":"20","author":"SZ Shalhout","year":"2023","unstructured":"Shalhout, S. Z., Miller, D. M., Emerick, K. S. & Kaufman, H. L. Therapy with oncolytic viruses: progress and challenges. Nat. Rev. Clin. Oncol. 20, 160\u2013177 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"8520_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11912-022-01341-w","volume":"25","author":"J Malhotra","year":"2023","unstructured":"Malhotra, J. & Kim, E. S. Oncolytic viruses and cancer immunotherapy. Curr. Oncol. Rep. 25, 19\u201328 (2023).","journal-title":"Curr. Oncol. Rep."},{"key":"8520_CR6","doi-asserted-by":"publisher","first-page":"e93103","DOI":"10.1371\/journal.pone.0093103","volume":"9","author":"Q Zhao","year":"2014","unstructured":"Zhao, Q. et al. A novel oncolytic herpes simplex virus type 2 has potent Anti-Tumor activity. PLoS One 9, e93103 (2014).","journal-title":"PLoS One"},{"key":"8520_CR7","doi-asserted-by":"publisher","first-page":"24672","DOI":"10.18632\/oncotarget.25122","volume":"9","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Stability and anti-tumor effect of oncolytic herpes simplex virus type 2. Oncotarget 9, 24672\u20132483 (2018).","journal-title":"Oncotarget"},{"key":"8520_CR8","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1089\/hum.2018.170","volume":"30","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Preclinical safety evaluation of oncolytic herpes simplex virus type 2. Hum. Gene Ther. 30, 651\u2013660 (2019).","journal-title":"Hum. Gene Ther."},{"key":"8520_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002224","volume":"9","author":"B Zhang","year":"2021","unstructured":"Zhang, B. et al. Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I\/II clinical trial. J. Immunother. Cancer 9, e2224 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"8520_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010662","volume":"13","author":"X Wang","year":"2025","unstructured":"Wang, X. et al. Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia\/Ib trial results and biomarker insights. J. Immunother. Cancer 13, e10662 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"8520_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010543","volume":"13","author":"Z Tan","year":"2025","unstructured":"Tan, Z. et al. Intratumoral oncolytic virus OH2 injection in patients with locally advanced or metastatic sarcoma: a phase 1\/2 trial. J. Immunother. Cancer 13, e10543 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"8520_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41591-023-02309-4","volume":"29","author":"H Soliman","year":"2023","unstructured":"Soliman, H. et al. Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. Nat. Med. 29, 450\u2013457 (2023).","journal-title":"Nat. Med."},{"key":"8520_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1089\/hum.2020.239","volume":"32","author":"W Zhang","year":"2020","unstructured":"Zhang, W. et al. Oncolytic herpes simplex virus type 2 can effectively inhibit colorectal cancer liver metastasis by modulating the immune status in the tumor microenvironment and inducing specific antitumor immunity. Hum. Gene Ther. 32, 203\u2013215 (2020).","journal-title":"Hum. Gene Ther."},{"key":"8520_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/sj.cgt.7700860","volume":"13","author":"BM Stiles","year":"2006","unstructured":"Stiles, B. M. et al. Minimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer. Cancer Gene Ther. 13, 53\u201364 (2006).","journal-title":"Cancer Gene Ther."},{"key":"8520_CR15","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.ymthe.2006.02.007","volume":"13","author":"X Fu","year":"2006","unstructured":"Fu, X. et al. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. Mol. Ther. 13, 882\u2013890 (2006).","journal-title":"Mol. Ther."},{"key":"8520_CR16","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/sj.cgt.7701033","volume":"14","author":"X Fu","year":"2007","unstructured":"Fu, X., Tao, L. & Zhang, X. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer. Cancer Gene Ther. 14, 480\u2013487 (2007).","journal-title":"Cancer Gene Ther."},{"key":"8520_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12985-022-01795-1","volume":"19","author":"H Hu","year":"2022","unstructured":"Hu, H. et al. A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7\u2009\u00d7\u2009CCL19 results in enhanced antitumor efficacy. Virol. J. 19, 74 (2022).","journal-title":"Virol. J."},{"key":"8520_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0092-8674(82)90409-3","volume":"31","author":"R Nusse","year":"1982","unstructured":"Nusse, R. & Varmus, H. E. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31, 99\u2013109 (1982).","journal-title":"Cell"},{"key":"8520_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Sig. Transduct. Target Ther. 7, 3 (2022).","journal-title":"Sig. Transduct. Target Ther."},{"key":"8520_CR20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.drudis.2021.07.007","volume":"27","author":"A Chatterjee","year":"2022","unstructured":"Chatterjee, A. et al. Advances in targeting the WNT\/\u03b2-catenin signaling pathway in cancer. Drug Discov. Today 27, 82\u2013101 (2022).","journal-title":"Drug Discov. Today"},{"key":"8520_CR21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.immuni.2006.12.007","volume":"26","author":"B Wu","year":"2007","unstructured":"Wu, B., Crampton, S. P. & Hughes, C. C. W. Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity 26, 227\u2013239 (2007).","journal-title":"Immunity"},{"key":"8520_CR22","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0002-9440(10)65204-2","volume":"155","author":"T Brabletz","year":"1999","unstructured":"Brabletz, T., Jung, A., Dag, S., Hlubek, F. & Kirchner, T. \u03b2-Catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am. J. Pathol. 155, 1033\u20131038 (1999).","journal-title":"Am. J. Pathol."},{"key":"8520_CR23","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1038\/onc.2009.82","volume":"28","author":"G Akiri","year":"2009","unstructured":"Akiri, G. et al. Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene 28, 2163\u20132172 (2009).","journal-title":"Oncogene"},{"key":"8520_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cell.2009.04.030","volume":"138","author":"DX Nguyen","year":"2009","unstructured":"Nguyen, D. X. et al. WNT\/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138, 51\u201362 (2009).","journal-title":"Cell"},{"key":"8520_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.pupt.2013.05.005","volume":"28","author":"X Fang","year":"2014","unstructured":"Fang, X. et al. \u03b2-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells. Pulm. Pharmacol. Ther. 28, 41\u201348 (2014).","journal-title":"Pulm. Pharmacol. Ther."},{"key":"8520_CR26","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.1158\/0008-5472.CAN-14-0184","volume":"74","author":"S Nakayama","year":"2014","unstructured":"Nakayama, S. et al. \u03b2-Catenin contributes to lung tumor development induced by EGFR mutations. Cancer Res. 74, 5891\u20135902 (2014).","journal-title":"Cancer Res."},{"key":"8520_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09289-5","volume":"10","author":"F Yang","year":"2019","unstructured":"Yang, F. et al. FBXW2 suppresses migration and invasion of lung cancer cells via promoting \u03b2-catenin ubiquitylation and degradation. Nat. Commun. 10, 1382 (2019).","journal-title":"Nat. Commun."},{"key":"8520_CR28","doi-asserted-by":"publisher","first-page":"6719","DOI":"10.1038\/s41388-020-01463-0","volume":"39","author":"JK Ochieng","year":"2020","unstructured":"Ochieng, J. K. et al. MBIP (MAP3K12 binding inhibitory protein) drives NSCLC metastasis by JNK-dependent activation of MMPs. Oncogene 39, 6719\u20136732 (2020).","journal-title":"Oncogene"},{"key":"8520_CR29","volume":"14","author":"JM Jeon","year":"2019","unstructured":"Jeon, J. M. et al. Secretome profiling of PC3\/nKR cells, a novel highly migrating prostate cancer subline derived from PC3 cells. PLoS One 14, e220807 (2019).","journal-title":"PLoS One"},{"key":"8520_CR30","doi-asserted-by":"publisher","first-page":"e02414","DOI":"10.1128\/JVI.02414-16","volume":"91","author":"C Su","year":"2017","unstructured":"Su, C. & Zheng, C. Herpes simplex virus 1 abrogates the cGAS\/STING-mediated cytosolic DNA-sensing pathway via its virion host shutoff protein, UL41. J. Virol. 91, e02414\u2013e02416 (2017).","journal-title":"J. Virol."},{"key":"8520_CR31","doi-asserted-by":"publisher","first-page":"e02056","DOI":"10.1128\/JVI.02056-16","volume":"91","author":"P Zhang","year":"2017","unstructured":"Zhang, P., Su, C., Jiang, Z. & Zheng, C. Herpes simplex virus 1 UL41 protein suppresses the IRE1\/XBP1 signal pathway of the unfolded protein response via its RNase activity. J. Virol. 91, e02056\u201316 (2017).","journal-title":"J. Virol."},{"key":"8520_CR32","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1099\/vir.0.030296-0","volume":"92","author":"X Yao","year":"2011","unstructured":"Yao, X. & Rosenthal, K. L. Herpes simplex virus type 2 virion host shutoff protein suppresses innate dsRNA antiviral pathways in human vaginal epithelial cells. J. Gen. Virol. 92, 1981\u20131993 (2011).","journal-title":"J. Gen. Virol."},{"key":"8520_CR33","doi-asserted-by":"publisher","first-page":"9341","DOI":"10.1128\/JVI.01008-06","volume":"80","author":"B Taddeo","year":"2006","unstructured":"Taddeo, B. & Roizman, B. The virion host shutoff protein (UL41) of herpes simplex virus 1 is an endoribonuclease with a substrate specificity similar to that of RNase A. J. Virol. 80, 9341\u20139345 (2006).","journal-title":"J. Virol."},{"key":"8520_CR34","doi-asserted-by":"publisher","first-page":"13115","DOI":"10.1128\/JVI.02167-13","volume":"87","author":"HL Zenner","year":"2013","unstructured":"Zenner, H. L., Mauricio, R., Banting, G. & Crump, C. M. Herpes simplex virus 1 counteracts tetherin restriction via its virion host shutoff activity. J. Virol. 87, 13115\u201313123 (2013).","journal-title":"J. Virol."},{"key":"8520_CR35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12985-015-0433-y","volume":"12","author":"C Su","year":"2015","unstructured":"Su, C., Zhang, J. & Zheng, C. Herpes simplex virus 1 UL41 protein abrogates the antiviral activity of hZAP by degrading its mRNA. Virol. J. 12, 203 (2015).","journal-title":"Virol. J."},{"key":"8520_CR36","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1073\/pnas.0400354101","volume":"101","author":"A Esclatine","year":"2004","unstructured":"Esclatine, A., Taddeo, B., Evans, L. & Roizman, B. The herpes simplex virus 1 UL41 gene-dependent destabilization of cellular RNAs is selective and may be sequence-specific. Proc. Natl. Acad. Sci. USA 101, 3603\u20133608 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"8520_CR37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ebiom.2018.04.026","volume":"31","author":"F Han","year":"2018","unstructured":"Han, F. et al. SOX30 inhibits tumor metastasis through attenuating Wnt-Signaling via transcriptional and posttranslational regulation of \u03b2-Catenin in lung cancer. EBioMedicine 31, 253\u2013266 (2018).","journal-title":"EBioMedicine"},{"key":"8520_CR38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.omto.2017.04.002","volume":"5","author":"JV Cockle","year":"2017","unstructured":"Cockle, J. V. et al. Oncolytic herpes simplex virus inhibits pediatric brain tumor migration and invasion. Mol. Ther. Oncolytics 5, 75\u201386 (2017).","journal-title":"Mol. Ther. Oncolytics"},{"key":"8520_CR39","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/nm.3391","volume":"19","author":"L Wan","year":"2013","unstructured":"Wan, L., Pantel, K. & Kang, Y. Tumor metastasis: moving new biological insights into the clinic. Nat. Med. 19, 1450\u20131464 (2013).","journal-title":"Nat. Med."},{"key":"8520_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2004.08.040","volume":"222","author":"J Mazieres","year":"2005","unstructured":"Mazieres, J., He, B., You, L., Xu, Z. & Jablons, D. M. Wnt signaling in lung cancer. Cancer Lett. 222, 1\u201310 (2005).","journal-title":"Cancer Lett."},{"key":"8520_CR41","first-page":"48","volume":"2","author":"G Bethune","year":"2010","unstructured":"Bethune, G., Bethune, D., Ridgway, N. & Xu, Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J. Thorac. Dis. 2, 48\u201351 (2010).","journal-title":"J. Thorac. Dis."},{"key":"8520_CR42","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.1158\/1078-0432.CCR-040007","volume":"10","author":"GV Scagliotti","year":"2004","unstructured":"Scagliotti, G. V., Selvaggi, G., Novello, S. & Hirsch, F. R. The biology of epidermal growth factor receptor in lung cancer. Clin. Cancer Res. 10, 4227\u20134232 (2004).","journal-title":"Clin. Cancer Res."},{"key":"8520_CR43","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde, P. M. et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. 386, 1973\u20131885 (2022).","journal-title":"N. Engl. J. Med."},{"key":"8520_CR44","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.omto.2019.10.003","volume":"15","author":"Y Zhu","year":"2019","unstructured":"Zhu, Y. et al. Enhanced therapeutic efficacy of a novel oncolytic herpes simplex virus type 2 encoding an antibody against programmed cell death 1. Mol. Ther. Oncolytics 15, 201\u2013213 (2019).","journal-title":"Mol. Ther. Oncolytics"},{"key":"8520_CR45","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1535-6108(03)00304-0","volume":"4","author":"Z Lu","year":"2003","unstructured":"Lu, Z., Ghosh, S., Wang, Z. & Hunter, T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of \u03b2-catenin, and enhanced tumor cell invasion. Cancer Cell 4, 499\u2013515 (2003).","journal-title":"Cancer Cell"},{"key":"8520_CR46","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.bcp.2004.09.019","volume":"69","author":"S Huang","year":"2005","unstructured":"Huang, S., Ho, C., Lin-Shiau, S. & Lin, J. Carnosol inhibits the invasion of B16\/F10 mouse melanoma cells by suppressing metalloproteinase-9 through down-regulating nuclear factor-kappaB and c-Jun. Biochem. Pharmacol. 69, 221\u2013232 (2005).","journal-title":"Biochem. Pharmacol."},{"key":"8520_CR47","first-page":"2953","volume":"27","author":"J Safranek","year":"2007","unstructured":"Safranek, J. et al. Expression of mRNA MMP-7 and mRNA TIMP-1 in non-small cell lung cancer. Anticancer Res. 27, 2953\u20132596 (2007).","journal-title":"Anticancer Res."},{"key":"8520_CR48","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/nrc2228","volume":"7","author":"C L\u00f3pez-Ot\u00edn","year":"2007","unstructured":"L\u00f3pez-Ot\u00edn, C. & Matrisian, L. M. Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 7, 800\u2013808 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"8520_CR49","first-page":"149","volume":"5","author":"T Iizasa","year":"1999","unstructured":"Iizasa, T. et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in Non-Small cell lung cancer patients. Clin. Cancer Res. 5, 149\u2013153 (1999).","journal-title":"Clin. Cancer Res."},{"key":"8520_CR50","first-page":"5967","volume":"62","author":"M Shiraga","year":"2002","unstructured":"Shiraga, M. et al. Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines. Cancer Res. 62, 5967\u20135973 (2002).","journal-title":"Cancer Res."},{"key":"8520_CR51","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.lungcan.2006.11.021","volume":"56","author":"J Rollin","year":"2007","unstructured":"Rollin, J. et al. Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer 56, 273\u2013280 (2007).","journal-title":"Lung Cancer"},{"key":"8520_CR52","first-page":"217","volume":"17","author":"P Iniesta","year":"2007","unstructured":"Iniesta, P. et al. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Oncol. Rep. 17, 217\u2013223 (2007).","journal-title":"Oncol. Rep."},{"key":"8520_CR53","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.lungcan.2007.07.005","volume":"58","author":"D Liu","year":"2007","unstructured":"Liu, D. et al. Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer. Lung Cancer 58, 384\u2013391 (2007).","journal-title":"Lung Cancer"},{"key":"8520_CR54","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/cancers10020028","volume":"10","author":"S Tada","year":"2018","unstructured":"Tada, S., Hamada, M. & Yura, Y. Proteomic analysis of secretomes of oncolytic herpes simplex virus-infected squamous cell carcinoma cells. Cancers 10, 28 (2018).","journal-title":"Cancers"},{"key":"8520_CR55","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.omto.2020.03.016","volume":"17","author":"T Koujima","year":"2020","unstructured":"Koujima, T. et al. Oncolytic virus-mediated targeting of the ERK signaling pathway inhibits invasive propensity in human pancreatic cancer. Mol. Ther. Oncolytics 17, 107\u2013117 (2020).","journal-title":"Mol. Ther. Oncolytics"},{"key":"8520_CR56","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.imbio.2007.09.005","volume":"212","author":"J Eisemann","year":"2008","unstructured":"Eisemann, J., M\u00fchl-Z\u00fcrbes, P., Steinkasserer, A. & Kummer, M. Infection of mature dendritic cells with herpes simplex virus type 1 interferes with the interferon signaling pathway. Immunobiol 212, 877\u2013886 (2008).","journal-title":"Immunobiol"},{"key":"8520_CR57","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.trsl.2021.10.006","volume":"240","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. NK cell tumor therapy modulated by UV-inactivated oncolytic herpes simplex virus type 2 and checkpoint inhibitors. Transl. Res. 240, 64\u201386 (2022).","journal-title":"Transl. Res."},{"key":"8520_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/srep22066","volume":"6","author":"C Zhou","year":"2016","unstructured":"Zhou, C. et al. Pygo2 functions as a prognostic factor for glioma due to its up-regulation of H3K4me3 and promotion of MLL1\/MLL2 complex recruitment. Sci. Rep. 6, 22066 (2016).","journal-title":"Sci. Rep."},{"key":"8520_CR59","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1080\/15548627.2020.1826689","volume":"17","author":"C Zhou","year":"2021","unstructured":"Zhou, C. et al. TSPAN1 promotes autophagy flux and mediates cooperation between WNT-CTNNB1 signaling and autophagy via the MIR454-FAM83A-TSPAN1 axis in pancreatic cancer. Autophagy 17, 3175\u20133195 (2021).","journal-title":"Autophagy"},{"key":"8520_CR60","doi-asserted-by":"publisher","first-page":"101309","DOI":"10.18632\/oncotarget.21087","volume":"8","author":"C Zhou","year":"2017","unstructured":"Zhou, C., Yu, J., Wang, M., Yang, J. & Tang, J. Identification of glycerol-3-phosphate dehydrogenase 1 as a tumour suppressor in human breast cancer. Oncotarget 8, 101309\u2013101324 (2017).","journal-title":"Oncotarget"},{"key":"8520_CR61","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13046-023-02788-w","volume":"42","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. MKRN1 promotes colorectal cancer metastasis by activating the TGF-\u03b2 signalling pathway through SNIP1 protein degradation. J. Exp. Clin. Canc. Res. 42, 219 (2023).","journal-title":"J. Exp. Clin. Canc. Res."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08520-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08520-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08520-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T07:06:02Z","timestamp":1757315162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08520-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8520"],"URL":"https:\/\/doi.org\/10.1038\/s42003-025-08520-y","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1115"}}